Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...

Eli Lilly (LLY) stock and Novo Nordisk (NONOF) stock are in focus as Medicare extends interim coverage for GLP-1 weight loss ...

Medicare's GLP-1 bridge program launches July 1 with a $50 monthly copay after major insurers rejected the original BALANCE ...

The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from ...

Two of the biggest insurance providers have expressed reluctance to participate in the government’s BALANCE program that ...

Alex Karnal, co-founder and CIO of Braidwell, a life sciences investment firm, spent 20 years building and backing biotech ...

Health insurers are raising questions about the Trump administration’s plan to cover obesity drugs in Medicare next year, casting doubt on whether enough insurers will sign on to the effort for it to ...

The federal government scrapped a plan to have health insurance companies fund coverage of obesity drugs for seniors, opting instead to pay for the medicine with taxpayer dollars through the ...

Trump team delays pilot program for Medicare to cover cost of ‘fat shot’ - Without insurance or discounts, GLP-1 injectables ...

Retailers race into GLP-1 market as Amazon and Walmart expand weight management programs, reshaping access and care delivery in obesity treatment.

The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 ...

President Donald Trump once promised lower prices on blockbuster weight-loss drugs in exchange for expanding access through ...